WuXi PharmaTech Provides Update of 2012 Financial Guidance, to Present at J.P. Morgan Healthcare Conference

SHANGHAI,  Jan. 7, 2013 -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in  China  and  the United States, today
announced that it will present at the 31th Annual J.P. Morgan Healthcare Conference on  Wednesday, January 9, 2013  at  8:30 a.m. Pacific Standard Time and updated its 2012 financial guidance. Based on preliminary, unaudited results, WuXi expects to achieve total revenues of approximately  $500 million and to meet the remainder of the 2012 financial guidance found in its third-quarter 2012 earnings release. 

WuXi plans to report its audited fourth-quarter and full-year 2012 financial results and to provide 2013 financial guidance in  March 2013.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Signant Health is ramping up its virtual trial model after buying VirTrial to “truly digitize the operations of clinical study sites.”

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.